<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Trials</journal-id><journal-id journal-id-type="iso-abbrev">Trials</journal-id><journal-title-group><journal-title>Trials</journal-title></journal-title-group><issn pub-type="epub">1745-6215</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26767505</article-id><article-id pub-id-type="pmc">4714444</article-id><article-id pub-id-type="publisher-id">1157</article-id><article-id pub-id-type="doi">10.1186/s13063-016-1157-z</article-id><article-categories><subj-group subj-group-type="heading"><subject>Study Protocol</subject></subj-group></article-categories><title-group><article-title>Dipeptidyl peptidase-4 inhibition and narrow-band ultraviolet-B light in psoriasis (DINUP): study protocol for a randomised controlled trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Lynch</surname><given-names>Maeve</given-names></name><address><email>lynchmaeve@yahoo.ie</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Ahern</surname><given-names>Tom&#x000e1;s B.</given-names></name><address><email>tomasbahern@physicians.ie</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Timoney</surname><given-names>Irene</given-names></name><address><email>irenetimoney@gmail.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Sweeney</surname><given-names>Cheryl</given-names></name><address><email>chsweene@tcd.ie</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Kelly</surname><given-names>Genevieve</given-names></name><address><email>gkellywinter@gmail.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Hughes</surname><given-names>Rosalind</given-names></name><address><email>rossiehughes@gmail.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Tobin</surname><given-names>Anne-Marie</given-names></name><address><email>tobin.annemarie@gmail.com</email></address><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>O&#x02019;Shea</surname><given-names>Donal</given-names></name><address><email>info@dosheaendo.ie</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Kirby</surname><given-names>Brian</given-names></name><address><email>b.kirby@st-vincents.ie</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><label/>Dermatology Department, St Vincent&#x02019;s University Hospital, Elm Park, Dublin 4, Ireland </aff><aff id="Aff2"><label/>Endocrinology Department, St Vincent&#x02019;s University Hospital, Elm Park, Dublin 4, Ireland </aff><aff id="Aff3"><label/>Dermatology Department, Adelaide and Meath Hospital Incorporating the National Children&#x02019;s Hospital, Tallaght, Dublin 24, Ireland </aff></contrib-group><pub-date pub-type="epub"><day>15</day><month>1</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>15</day><month>1</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>17</volume><elocation-id>29</elocation-id><history><date date-type="received"><day>3</day><month>4</month><year>2015</year></date><date date-type="accepted"><day>6</day><month>1</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; Lynch et al. 2016</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Moderate to severe psoriasis is a systemic inflammatory disease associated with insulin resistance, obesity and type 2 diabetes (T2DM). Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that improves glycaemia and has a marketing authorisation for the treatment of T2DM. Non-immunosuppressive therapies that are effective for psoriasis and its associated comorbidities would be a significant advance in the treatment of this chronic disease.</p></sec><sec><title>Methods/Design</title><p>This is a single centre, 39-week, prospective, randomised, open label, clinical trial of oral sitagliptin (Januvia<sup>&#x000ae;</sup>) in psoriasis patients who are due to undergo a course of narrow-band ultraviolet-B (NB-UVB) phototherapy. We plan to enrol 120 participants and allocate participants on a random and 1:1 basis to receive sitagliptin 100&#x000a0;mg daily for 24&#x000a0;weeks combined with NB-UVB or NB-UVB monotherapy. Participants will be followed up for 12&#x000a0;weeks after sitagliptin therapy is discontinued. The primary endpoint is the change in Psoriasis Area and Severity Index (PASI) 24&#x000a0;weeks after treatment initiation. Secondary endpoints include cumulative NB-UVB dose, number of NB-UVB treatments required to clear psoriasis, proportions of participants who achieve PASI-50 (50&#x000a0;% reduction in PASI from baseline), PASI-75, PASI-90 and the proportion of participants who relapse in each group. We will also analyse changes in cardiovascular disease risk factors, serum cytokine and hormone levels and peripheral blood mononuclear expression of immune proteins at 24 and 36&#x000a0;weeks. A subgroup of participants will have skin biopsies taken and analysed for skin levels and expression of immune cells, receptors, hormones and immune proteins. The genetic or epigenetic profile that predicts best response to DPP-4 inhibitor therapy will be analysed. The safety endpoints include the rate and severity of adverse events.</p></sec><sec><title>Discussion</title><p>This is the first randomised clinical trial assessing dipeptidyl peptidase-4 inhibition therapy in psoriasis. We hypothesise that sitagliptin therapy in combination with NB-UVB improves psoriasis severity compared to NB-UVB monotherapy.</p></sec><sec><title>Trial registration</title><p>ClinicalTrials.gov Identifier <ext-link ext-link-type="uri" xlink:href="https://www.clinicaltrials.gov/ct2/show/NCT02347501">NCT02347501</ext-link> (Date of registration: 27 January 2015).</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Psoriasis</kwd><kwd>Dipeptidyl peptidase-4 inhibition</kwd><kwd>Sitagliptin</kwd><kwd>Psoriasis area and severity index</kwd><kwd>Narrow-band ultraviolet-B phototherapy</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>Psoriasis is a common immune-mediated skin disease affecting 1.3&#x02013;2.2&#x000a0;% of the UK population [<xref ref-type="bibr" rid="CR1">1</xref>] with chronic plaque psoriasis being the most common (90&#x000a0;%) form [<xref ref-type="bibr" rid="CR2">2</xref>]. The majority of patients have mild psoriasis although around 20&#x02013;30&#x000a0;% of patients have more severe involvement that warrants consideration of systemic therapy [<xref ref-type="bibr" rid="CR3">3</xref>]. Treatment options for severe psoriasis include systemic immunosuppressant therapies such as methotrexate and fumaric acid esters which are effective but associated with potential toxicities. Biologic therapies have revolutionised the management of psoriasis but are expensive and are immunosuppressive. Psoriasis has a significant impact on quality of life and those patients with severe disease have an approximately 4-year reduction in life span [<xref ref-type="bibr" rid="CR4">4</xref>]. Moderate to severe psoriasis is associated with smoking, alcohol excess, obesity and type 2 diabetes (T2DM) [<xref ref-type="bibr" rid="CR5">5</xref>]. These comorbidities likely contribute to increased cardiovascular risk and premature mortality [<xref ref-type="bibr" rid="CR6">6</xref>] as does the systemic inflammation associated with psoriasis [<xref ref-type="bibr" rid="CR7">7</xref>]. An effective treatment for psoriasis that is non-immunosuppressive and treats comorbidities such as diabetes would, therefore, be very welcome.</p><p>Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that has a marketing authorisation for T2DM. Sitagliptin has placebo-like tolerability and a good safety profile. Two case reports have shown that sitagliptin improved psoriasis severity [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. Dipeptidyl peptidase-4 is expressed on keratinocytes and its activity is upregulated in psoriasis [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. The main site of DPP-4 activity is CD26. CD26 is a marker of T cell activation and is a key molecule in the pathogenesis of autoimmune diseases [<xref ref-type="bibr" rid="CR12">12</xref>]. Agents used to treat psoriasis commonly target the underlying inflammation [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. C-reactive protein (CRP) is a sensitive, systemic marker of inflammation [<xref ref-type="bibr" rid="CR15">15</xref>]. In people with T2DM DPP-4 inhibitor therapy decreases CRP concentrations [<xref ref-type="bibr" rid="CR16">16</xref>&#x02013;<xref ref-type="bibr" rid="CR22">22</xref>]. Serum CRP concentrations correlate with psoriasis severity and interventions that decrease the CRP concentration may decrease also psoriasis severity [<xref ref-type="bibr" rid="CR23">23</xref>&#x02013;<xref ref-type="bibr" rid="CR25">25</xref>].</p><p>We have shown previously, in psoriasis patients without T2DM (both lean and obese), that homeostasis model assessment of insulin resistance (HOMA-IR) values correlate with those of the Psoriasis Area and Severity Index (PASI, a measure of psoriasis severity: <italic>r</italic>&#x02009;=&#x02009;0.49, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) [<xref ref-type="bibr" rid="CR26">26</xref>].</p><p>Medications that improve insulin action may also decrease systemic inflammation and improve psoriasis [<xref ref-type="bibr" rid="CR27">27</xref>]. This study aims to assess the efficacy and safety of sitagliptin, a DPP-4 inhibitor, in patients with psoriasis without diabetes undergoing narrow-band ultraviolet-B (NB-UVB) phototherapy. We hypothesise that sitagliptin therapy improves psoriasis severity.</p></sec><sec id="Sec2"><title>Methods/Design</title><sec id="Sec3"><title>Study design and study organisation</title><p>This will be a single centre, 39-week, prospective, randomised, open label, clinical trial of oral sitagliptin tablets (Januvia<sup>&#x000ae;</sup>) in psoriasis patients who are due to undergo a course of NB-UVB phototherapy. We plan to enrol 120 research participants in total. Participants will be allocated at random to receive either (a) 24&#x000a0;weeks of sitagliptin (Januvia<sup>&#x000ae;</sup>, 100&#x000a0;mg daily, or 50&#x000a0;mg daily for participants with moderate kidney disease) with NB-UVB phototherapy; or (b) NB-UVB phototherapy without any additional treatment. The primary outcome measure is the change in the psoriasis area and severity index (&#x02206;PASI) during 24&#x000a0;weeks of treatment. This parameter, along with secondary outcome measures, will be compared between the two groups. This study has been approved by the St Vincent&#x02019;s University Hospital Ethics and Medical Research Committee and by the Health Products Regulatory Authority of Ireland.</p><p>This study will be carried out in compliance with the study protocol and in accordance with the sponsor/contract research organisations&#x02019; standard operating procedures. These are designed to ensure adherence to Good Clinical Practice (GCP) guidelines, as described in the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Harmonised Tripartite Guidelines for Good Clinical Practice, 1996.</p></sec><sec id="Sec4"><title>Trial registration</title><p>Ethical approval number: DPIP-2012-02</p><p>Date of approval: 19 June 2013</p><p>ClinicalTrials.gov Identifier: NCT02347501</p><p>EudraCT: 2012-005483-10</p></sec><sec id="Sec5"><title>Data handling</title><p>All data will be stored securely. Details of outcome measures and adverse events will be documented in hospital healthcare records, in individual research participant case report forms and in an encrypted electronic database.</p><p>The study investigators will adhere to hospital protocols pertaining to healthcare record use and storage. To protect the research participant&#x02019;s identity, a unique identification code will be assigned by the investigator, or authorised designee, to each study participant and used in lieu of the participant&#x02019;s name when the investigator reports adverse events and/or other study-related data are reported.</p></sec><sec id="Sec6"><title>Participants</title><p>Potentially eligible research participants will be identified through use of a patient database and through review of healthcare records in St Vincent&#x02019;s University Hospital. Potentially eligible research participants will be recruited in one of two ways by one of the study investigators or by a suitably qualified designee. One of these two ways will be during a clinic visit and the other will be by mailing a letter of invitation.</p><p>Psoriasis patients attending this centre who have a PASI greater than 7, and who are due to undergo NB-UVB phototherapy, will be considered potentially eligible research participants and will be invited to attend for a screening visit. Informed consent will be obtained from every participant in the trial. The PASI will be measured at every visit by a senior clinician, or suitably qualified designee. The PASI assessor will be blinded to the participant&#x02019;s randomisation group. After a 3-week period, where research participants will not receive the investigational medicinal product, those research participants who meet all of the inclusion criteria and do not fall under any of the exclusion criteria (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>) will be allocated randomly, after stratification by glycated haemoglobin (HbA1c) level (HbA1c &#x0003c;38&#x000a0;mmol/mol or &#x02265;38&#x000a0;mmol/mol), body mass index level (BMI &#x0003c;30&#x000a0;kg/m<sup>2</sup> or &#x02265;30&#x000a0;kg/m<sup>2</sup>) and previous response to NB-UVB (achieved remission within 25 exposures during most recent course of NB-UVB or not), either to arm A or to arm B. Those who have not been exposed previously to NB-UVB will be placed in the &#x02018;did not achieve remission within 25 exposures&#x02019; group.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Inclusion and exclusion criteria</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Inclusion criteria</th><th>Exclusion criteria</th></tr></thead><tbody><tr><td>1. Patients who have a diagnosis of generalised chronic plaque and/or guttate psoriasis</td><td>1. Patients with photosensitive disorders</td></tr><tr><td>2. Male and female patients aged between 18 and 75&#x000a0;years inclusive</td><td>2. Patients with diabetes mellitus</td></tr><tr><td>3. Patients with a PASI of 7 or greater at screening or baseline despite use of topical therapies</td><td>3. Patients who are receiving medications that can cause photosensitivity</td></tr><tr><td>4. Patients who are due to undergo NB-UVB light therapy</td><td>4. Patient who are receiving GLP-1 analogue therapy</td></tr><tr><td>5. Patients who have not required systemic psoriasis therapy during the past 8&#x000a0;weeks</td><td>5. Patients who have conditions that could be made worse by phototherapy (cataracts, epilepsy, etc.)</td></tr><tr><td>6. Patients who are unlikely to require systemic therapy for the duration of clinical trial involvement</td><td>6. Patients with allergy or hypersensitivity to Januvia<sup>&#x000ae;</sup>
</td></tr><tr><td>7. Patients who have a negative pregnancy test at screening (women of child-bearing potential only)</td><td>7. Patients with any of the following conditions:<break/>severe kidney disease (estimated glomerular filtration rate of less than 30&#x000a0;ml/min/1.73&#x000a0;m<sup>2</sup>)<break/>severe heart disease (left ventricular ejection fraction less than 35&#x000a0;%)<break/>severe liver disease (alanine aminotransferase greater than 150&#x000a0;IU/L)<break/>severe lung disease (forced expiratory volume in 1&#x000a0;second or a forced vital capacity that is known to be less than 50&#x000a0;% of that estimated for a person of that age and gender)</td></tr><tr><td>8. Patients who are willing to sign voluntarily a statement of informed consent to participate in the study</td><td>8. Patients who have received NB-UVB light recently (within 8&#x000a0;weeks)</td></tr><tr><td/><td>9. Patients who are receiving currently or have received systemic therapy for psoriasis recently (within 8&#x000a0;weeks)</td></tr><tr><td/><td>10. Patients who have any other contraindications to Januvia<sup>&#x000ae;</sup> as stated in its Summary of Product Characteristics</td></tr><tr><td/><td>11. Female patients of child-bearing potential who are pregnant, breastfeeding, or unwilling to practice an acceptable barrier and/or hormonal method of contraception during participation in the study &#x02013; abstinence will be permitted only if it is in keeping with a person&#x02019;s lifestyle</td></tr><tr><td/><td>12. Patients with any clinically significant chronic disease that might, in the opinion of the investigator, interfere with the evaluations or preclude completion of the trial</td></tr><tr><td/><td>13. Patients with a current or recent (within the past 4&#x000a0;weeks) acute serious illness, acute psychiatric illness or severe uncontrolled/unstable illness</td></tr><tr><td/><td>14. Patients who have been randomised into this study previously</td></tr><tr><td/><td>15. Patients who are participating in another clinical trial concurrently</td></tr><tr><td/><td>16. Patients who are participating in another clinical trial during the 12&#x000a0;weeks prior to study entry (i.e. screening visit)</td></tr></tbody></table><table-wrap-foot><p>
<italic>GLP-1</italic> glucagon-like peptide-1 analogue, <italic>NB-UVB</italic> narrow-band ultraviolet-B phototherapy, <italic>PASI</italic> psoriasis area and severity index</p></table-wrap-foot></table-wrap></p><p>In order to achieve this we have prepared eight randomisation lists using a web-based random generator programme (<ext-link ext-link-type="uri" xlink:href="http://www.randomization.com">http://www.randomization.com</ext-link>). For each participant the investigator, or authorised designee, will chose the appropriate list and will add the participant&#x02019;s identifier to the list in chronological order. This list will be thereby used to determine the study treatment which the participant will receive. Random allocation will occur at visit 2 (baseline visit) once all screening procedures required at visit 1 (screening visit) have been completed, once it has been confirmed that the participant satisfies all inclusion and exclusion criteria and once the participant completes the 3-week run-in period. Identification numbers will be assigned chronologically in consecutive, ascending order.</p></sec><sec id="Sec7"><title>Study treatments</title><p>Research participants allocated to arm A will receive a 26-week supply of Januvia<sup>&#x000ae;</sup> tablets (DPP-4 inhibitor) and will be instructed to ingest orally one 100&#x000a0;mg tablet once daily (or 50&#x000a0;mg once daily for participants with moderate kidney disease) for 24&#x000a0;weeks (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). Research participants allocated to arm B will receive no treatment (aside from usual medications and phototherapy). Both the research participants and the investigators will be aware of the trial arm to which the research participant has been allocated randomly (open-label study).<fig id="Fig1"><label>Figure 1</label><caption><p>Depiction of the flow of research participants through each stage of the study: randomisation of research participants to one of two study arms, stages of no treatment and of treatment, and the medications that will be received by participants at each stage of the study</p></caption><graphic xlink:href="13063_2016_1157_Fig1_HTML" id="MO1"/></fig></p><p>All research participants will undergo NB-UVB phototherapy during the initial portion of study participation. This protocol involves whole-body NB-UVB using a Waldmann UV5001 cabinet incorporating 40 100-watt Philips TL-01 fluorescent lamps (emitting within the wavelength range of 311&#x000a0;nm to 313&#x000a0;nm) on Mondays, Wednesdays and Fridays. Doses of NB-UVB are adjusted according to the minimal erythema dose (MED) and according to erythemal response to therapy [<xref ref-type="bibr" rid="CR28">28</xref>]. The MED is established by exposing eight 1.5&#x02009;&#x000d7;&#x02009;1.5&#x000a0;cm sites of unaffected skin of the upper back to NB-UVB at various doses (50, 70, 100, 140, 200, 280, 390, 550, 770 and 1080&#x000a0;mJ/cm<sup>2</sup>) from a bank of four TL-01 fluorescent tubes. The MED is defined as the dose that causes barely perceptible erythema 24&#x000a0;hours after irradiation. The first dose is 70&#x000a0;% of the MED and incremental increases are made at each visit to a maximum dose of 3833&#x000a0;mJ/cm<sup>2</sup>. Patients are treated until psoriasis clears or until they have received 40 exposures. All psoriasis patients wear protective UV goggles and the men wear genital protection. Irradiance is measured each month using an IL1400A radiometer and SEL240/UVB-1/TD detector head that is calibrated annually against a reference standard.</p><p>Research participants are prohibited from using systemic psoriasis therapy for the duration of their trial involvement. Any other medications that are considered necessary for the participant&#x02019;s welfare and will not interfere with the study medication will be given at the discretion of the investigator.</p></sec><sec id="Sec8"><title>Safety</title><p>Comprehensive assessments of any apparent toxicity experienced by the research participant will be performed throughout the course of the study from the time of participant&#x02019;s signature of informed consent. The safety of the investigational medicinal products will be assessed through the recording, reporting and analysing of baseline medical conditions, adverse events, vital signs and laboratory tests (full blood count, renal and liver blood tests). Information about all serious adverse events (SAEs) will be collected and recorded on the SAE Report Form. Each SAE must be reported by the investigator, or an authorised designee, to the sponsor within 24&#x000a0;hours of learning of its occurrence.</p></sec><sec id="Sec9"><title>Endpoints</title><p>Efficacy and safety measures will be performed according to a schedule of assessments (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Schedule of assessments</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Screening visit (week 3)</th><th>Baseline visit (day 0)</th><th>First treatment visit (week 3&#x02009;&#x000b1;&#x02009;7&#x000a0;days)</th><th>Second treatment visit (week 6&#x02009;&#x000b1;&#x02009;7&#x000a0;days)</th><th>Third treatment visit (week 12&#x02009;&#x000b1;&#x02009;7&#x000a0;days)</th><th>Fourth treatment visit (week 24&#x02009;&#x000b1;&#x02009;7&#x000a0;days)</th><th>First follow-up visit (week 30&#x02009;&#x000b1;&#x02009;7&#x000a0;days))</th><th>End of study visit (week 36&#x02009;&#x000b1;&#x02009;7&#x000a0;days)</th><th>Early withdrawal visit</th></tr></thead><tbody><tr><td>Visit number</td><td>1</td><td>2</td><td>3</td><td>4</td><td>5</td><td>6</td><td>7</td><td>8</td><td/></tr><tr><td>Informed consent</td><td>X</td><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Inclusion/exclusion criteria</td><td>X</td><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Demographic data</td><td>X</td><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Medical history</td><td>X</td><td/><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Quality of life assessments</td><td/><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td>Concomitant medication</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td>Height</td><td/><td>X</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>Weight</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td>Blood pressure and heart rate</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td>PASI assessment</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td>Blood samples<sup>b</sup>
</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td>Urinary pregnancy test (women of child-bearing potential only)</td><td>X</td><td>X</td><td/><td/><td/><td/><td/><td>X</td><td>X</td></tr><tr><td>Adverse event assessment</td><td/><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td>IMP dispensing (arm A)</td><td/><td>X</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>IMP accountability return and compliance check</td><td/><td/><td>X</td><td>X</td><td>X</td><td>X</td><td/><td/><td>X<sup>a</sup>
</td></tr></tbody></table><table-wrap-foot><p>
<sup>a</sup>if applicable</p><p>
<sup>b</sup>safety and efficacy variables</p><p>
<italic>IMP</italic> Investigational Medicinal Product, <italic>PASI</italic> Psorasis Area and Severity Index</p></table-wrap-foot></table-wrap></p><p>The primary efficacy endpoint is the change in the PASI (&#x00394;PASI) after 24&#x000a0;weeks.</p><p>The secondary endpoints will include the:<list list-type="order"><list-item><p>&#x00394;PASI after 36&#x000a0;weeks</p></list-item><list-item><p>Change in validated quality of life scores (Dermatology Life Quality Index (DLQI), EuroQol 5 item questionnaire (EQ-5D), Hospital anxiety and Depression Scale (HADS), and Stanford Health Assessment Questionnaire 8-Item Disability Scale (HAQ-8) after 24 and 36&#x000a0;weeks</p></list-item><list-item><p>NB-UVB light dosage and exposure number at 36&#x000a0;weeks</p></list-item><list-item><p>Proportion of patients who achieve a greater than 50&#x000a0;% reduction in PASI from baseline (PASI-50) by 36&#x000a0;weeks</p></list-item><list-item><p>Proportion of participants who achieve PASI-75 and PASI-90 by 36&#x000a0;weeks</p></list-item><list-item><p>Proportion of participants who relapse (PASI greater than 50&#x000a0;% of baseline value) by 36&#x000a0;weeks</p></list-item><list-item><p>Times taken to achieve PASI-50, PASI-75, PASI-90 and relapse</p></list-item><list-item><p>Changes in levels of cardiovascular disease risk factors (blood pressure, glycaemic measures lipid fractions, weight, etc.) after 24 and 36&#x000a0;weeks</p></list-item><list-item><p>Changes in serum concentrations of cytokines and hormones after 24 and 36&#x000a0;weeks</p></list-item><list-item><p> Changes in peripheral blood mononuclear cell expression of immune proteins (interleukin (IL)-6, tumour necrosis factor alpha (TNF&#x003b1;), IL-10, IL-17, interferon gamma, toll-like receptor 4, toll-like receptor 2, c-Jun N-terminal protein kinase 1, monocyte chemoattractant protein-1, etc.) after 24 and 36&#x000a0;weeks</p></list-item></list></p><p>The tertiary efficacy endpoints, which will be determined only in a subgroup of willing clinical trial participants, are the:<list list-type="order"><list-item><p>Changes in skin levels and expression of cells, hormones, receptors, enzymes and immune proteins after 24&#x000a0;weeks; and</p></list-item><list-item><p>Genetic, and/or epigenetic, profile that predicts best response to phototherapy and to DPP-4 inhibitor therapy</p></list-item></list></p><p>The safety endpoints will include:<list list-type="order"><list-item><p>Full blood count</p></list-item><list-item><p>Renal and liver blood tests</p></list-item><list-item><p>Skin reactions (erythema, pruritus, stinging and lesional blistering)</p></list-item><list-item><p>Reactivation of herpes simplex infection</p></list-item><list-item><p>Other adverse events</p></list-item></list></p></sec><sec id="Sec10"><title>Statistical methods and sample size</title><p>Demographic and baseline clinical data will be summarised using descriptive statistics according to treatment group. The primary and secondary efficacy variables and the safety variables will be summarised using descriptive statistics according to treatment group.</p><p>Data from research participants who are not allocated to either arm of the study <italic>and</italic> who do not receive a supply&#x000a0;of investigational medicinal product will be excluded from statistical analyses.</p><p>The analysis of the data will be based on an intention-to-treat approach. <italic>T</italic> tests (or the appropriate alternative for non-parametric data), using two-sided tests, will be used to determine whether significant differences between the sets of data exist (SPSS version 20.0, IBM, Armonk, NY, USA). The independent samples <italic>T</italic> test will be used to assess for differences between the effects of the test product (Januvia<sup>&#x000ae;</sup>) compared to the effects of no additional treatment. Chi-square analyses will be used to test for significant differences in categorical variables between the sets of data obtained. Missing data will be dealt with using last observation carried forward.</p><p>Subgroup analyses will be performed on those research participants who:<list list-type="order"><list-item><p>Complete the visit 6 assessment</p></list-item><list-item><p>Have severe psoriasis</p></list-item><list-item><p>Have non-severe psoriasis</p></list-item><list-item><p>Are male</p></list-item><list-item><p>Are female</p></list-item><list-item><p>Are obese</p></list-item><list-item><p>Are older than 45&#x000a0;years</p></list-item></list></p><p>We plan to enrol 120 research participants in total.</p><p>Kleinpenning et al. have determined previously the effect of two different NB-UVB phototherapy regimens on the decrease in PASI 3&#x000a0;months after completion of a course of NB-UVB phototherapy [<xref ref-type="bibr" rid="CR29">29</xref>]. Three months after cessation of NB-UVB light therapy the decrease in the PASI in those receiving an high-dose regimen was 5.93&#x02009;&#x000b1;&#x02009;4.1 compared to baseline. This decrease in PASI was significantly less in the group receiving a low-dose regimen (4.14&#x02009;&#x000b1;&#x02009;2.96, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05).</p><p>Based on these data, and assuming a 20&#x000a0;% dropout rate, we have calculated that we will require 60 research participants (in each randomisation arm) to detect a greater than 33&#x000a0;% difference in the &#x02206;PASI with 80&#x000a0;% power and a 5&#x000a0;% significance level.</p></sec><sec id="Sec11"><title>Quality control of the study</title><p>A quality assurance audit may be conducted by the sponsor or its agent at any time during, or shortly after, the study. The investigator will permit an independent audit by an auditor mandated by the sponsor, after reasonable notice. The purpose of an audit is to confirm that the study is conducted as per protocol, Good Clinical Practice and applicable regulatory requirements, that the rights and well-being of the patients enrolled have been protected, and that the data relevant for the evaluation of the investigational medicinal product have been captured, processed and reported in compliance with the planned arrangements. The investigator will permit direct access to all study documents, drug accountability records, medical records and source data.</p><p>A future report will follow the Consolidated Standards of Reporting Trials (CONSORT) statement.</p></sec></sec><sec id="Sec12"><title>Discussion</title><p>Psoriasis is characterised by keratinocyte hyperproliferation, by aberrant keratinocyte differentiation and by cutaneous inflammation [<xref ref-type="bibr" rid="CR10">10</xref>].</p><p>The high concentration of DPP-4 expressed on keratinocytes and the fact that DPP-4 inhibition suppresses keratinocyte proliferation in vitro, and restores partially keratinocyte differentiation in vivo [<xref ref-type="bibr" rid="CR30">30</xref>], support a potential role for DPP-4 inhibition therapy in the treatment of psoriasis. Two cases of DPP-4 inhibitor therapy improving psoriasis severity have been reported [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. One of these two cases was a woman in our department with severe psoriasis without diabetes who developed systemic B-cell lymphoma [<xref ref-type="bibr" rid="CR9">9</xref>]. Treatment with methotrexate and acitretin were not tolerated or failed, and in the setting of the patient&#x02019;s concomitant malignancy, sitagliptin was commenced in preference to an immunosuppressive therapy. After 8&#x000a0;weeks of oral sitagliptin treatment (100&#x000a0;mg once daily) the psoriasis body surface area (BSA) involvement decreased to less than 1&#x000a0;%.</p><p>DPP-4 inhibitors also prevent the degradation of insulin secretagogues such as glucagon-like peptide-1 (GLP-1), thereby ameliorating hyperglycaemia without causing hypoglycaemia [<xref ref-type="bibr" rid="CR31">31</xref>]. Because of these effects, DPP-4 inhibitors are licensed for the treatment of T2DM. Other interventions that increase GLP-1 receptor activation, such as roux-en-Y gastric bypass surgery and GLP-1 analogue therapy, can also improve psoriasis severity [<xref ref-type="bibr" rid="CR32">32</xref>&#x02013;<xref ref-type="bibr" rid="CR34">34</xref>].</p><p>We have previously reported a significant improvement in two patients with psoriasis and concomitant diabetes treated with the GLP-1 analogue liraglutide [<xref ref-type="bibr" rid="CR33">33</xref>]. In a subsequent open study of seven patients with both psoriasis and type 2 diabetes we reported a significant reduction in psoriasis severity and a significant improvement in quality of life following treatment with liraglutide [<xref ref-type="bibr" rid="CR35">35</xref>]. The median PASI decreased from 4.8 to 3.0 (<italic>p</italic>&#x02009;=&#x02009;0.03) and median DLQI from 6.0 to 2.0 (<italic>p</italic>&#x02009;=&#x02009;0.03). The improvement in patients treated with liraglutide was associated with an increase in circulating invariant natural killer T (iNKT) cells, innate T cells implicated in psoriasis pathogenesis, and a relative decrease in iNKT cell number in psoriatic plaques.</p><p>Another study evaluated seven patients treated with either exenatide or liraglutide for several months and found a significant reduction in PASI of 2.8 (from 12.0&#x02009;&#x000b1;&#x02009;5.9 to 9.2&#x02009;&#x000b1;&#x02009;6.4; <italic>p</italic>&#x02009;=&#x02009;0.04) and a slight reduction in epidermal thickness (from 0.47&#x02009;&#x000b1;&#x02009;0.12 to 0.40&#x02009;&#x000b1;&#x02009;0.15&#x000a0;mm; <italic>p</italic>&#x02009;=&#x02009;0.06). The decrease in PASI was associated with a decrease in &#x003a5;&#x003b4;-T cell number from 6.7&#x02009;&#x000b1;&#x02009;4.5 to 2.7&#x02009;&#x000b1;&#x02009;3.8&#x000a0;% (<italic>p</italic>&#x02009;=&#x02009;0.05) and IL-17 expression (<italic>p</italic>&#x02009;&#x0003e;&#x02009;0.05), both of which are involved in the pathogenesis of psoriasis [<xref ref-type="bibr" rid="CR36">36</xref>]. These improvements in psoriasis are noted before weight loss occurs [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR36">36</xref>] and are not associated with improved glycaemic control [<xref ref-type="bibr" rid="CR33">33</xref>&#x02013;<xref ref-type="bibr" rid="CR35">35</xref>].</p><p>A randomised clinical trial evaluated liraglutide in 20 obese glucose-tolerant patients with psoriasis [<xref ref-type="bibr" rid="CR37">37</xref>]. After 8&#x000a0;weeks of treatment there was no significant difference in the change in PASI between the liraglutide group and the placebo group. There was a significant change in PASI from baseline in the liraglutide group and not in the placebo group. This was a small study (<italic>n</italic>&#x02009;=&#x02009;20) and the study duration of 8&#x000a0;weeks was short.</p><p>Dipeptidyl peptidase-4 is expressed as CD26 on T cells. One hypothesis of sitagliptin&#x02019;s potential effect in psoriasis treatment is that inhibition of DPP-4 may inhibit T cell activation and improve psoriasis. While there is evidence that sitagliptin decreases systemic inflammation, which may account for the reason it may be beneficial in psoriasis, there is no evidence to suggest that sitagliptin therapy is immunosuppressive. In one cross-over study of 36 patients with T2DM treated with sitagliptin or placebo, molecular markers of inflammation were altered significantly in the sitagliptin group [<xref ref-type="bibr" rid="CR21">21</xref>]. Sitagliptin therapy (100&#x000a0;mg daily for 6&#x000a0;weeks) reduced serum concentrations of the inflammatory markers CRP, IL-6, IL-18 and reduced concentrations of the soluble cell adhesion proteins, intercellular adhesion molecule 1 and E-selectin (molecules involved in the development of atherosclerosis) in patients with T2DM. The change in CRP was correlated inversely with a rise in GLP-1 levels supporting a role for GLP-1 release, as well as with improved glucose-insulin homeostasis, in the improvement in systemic inflammatory and endothelial markers. A reduction in CRP has been demonstrated in other studies of patients with T2DM treated with sitagliptin [<xref ref-type="bibr" rid="CR16">16</xref>&#x02013;<xref ref-type="bibr" rid="CR22">22</xref>] although no change in CRP has also been reported with sitagliptin therapy [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. One of the studies demonstrating the anti-inflammatory action of sitagliptin involved 22 obese patients with T2DM who were allocated at random to receive sitagliptin 100&#x000a0;mg daily or placebo for 12&#x000a0;weeks [<xref ref-type="bibr" rid="CR22">22</xref>]. In this study peripheral blood mononuclear cell expression of the inflammatory molecules CD26 and TNF&#x003b1; decreased with sitagliptin therapy as did serum concentrations of inflammatory markers. Expression of CD26 decreased after a single dose of sitagliptin and the authors suggested that sitagliptin therapy, in addition to inhibiting the action of DPP-4, may inhibit synthesis of DPP-4.</p><p>Sitagliptin monotherapy has demonstrated improvements in measures of pancreatic &#x003b2; cell function (insulin secretion) as determined by the homeostasis model assessment-&#x003b2; cell function (HOMA-&#x003b2;) in the majority of studies evaluating both sitagliptin as monotherapy [<xref ref-type="bibr" rid="CR40">40</xref>&#x02013;<xref ref-type="bibr" rid="CR44">44</xref>] or sitagliptin as an adjunctive therapy [<xref ref-type="bibr" rid="CR45">45</xref>&#x02013;<xref ref-type="bibr" rid="CR49">49</xref>]. Improvements in insulin resistance have shown varied results. The majority of studies have shown improvements in insulin resistance when sitagliptin is used as an adjunctive treatment [<xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR48">48</xref>&#x02013;<xref ref-type="bibr" rid="CR50">50</xref>] rather than as monotherapy [<xref ref-type="bibr" rid="CR41">41</xref>&#x02013;<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR51">51</xref>]. One study of sitagliptin monotherapy has demonstrated that insulin resistance improved [<xref ref-type="bibr" rid="CR40">40</xref>]. A meta-analysis of seven studies comparing sitagliptin to metformin found that sitagliptin was inferior to metformin in improving insulin resistance (<italic>p</italic>&#x02009;=&#x02009;0.003) [<xref ref-type="bibr" rid="CR52">52</xref>]. The majority of these studies measured insulin resistance using HOMA-IR, which correlates well with the euglycaemic clamp, which is the &#x02018;gold standard&#x02019; for measuring insulin resistance [<xref ref-type="bibr" rid="CR53">53</xref>]. Limitations associated with the use of HOMA-IR include lack of consensus regarding cut-off values and decreased reliability in lean patients with T2DM (due to lower &#x003b2; cell function and higher fasting glucose levels).</p><p>Sitagliptin treatment has not demonstrated immunosuppressive effects in healthy individuals. One study evaluated sitagliptin 100&#x000a0;mg daily compared to placebo for 28&#x000a0;days in healthy volunteers and measured immune function [<xref ref-type="bibr" rid="CR54">54</xref>]. There was no effect on cytokines measured including the immunosuppressive cytokine, transforming growth factor &#x003b2;, on major lymphocyte subsets and on numbers of regulatory T cells suggesting that sitagliptin lacks immunomodulatory effects in healthy patients. A non-sustained increase in CD26 levels in T cells and increase in memory CD8<sup>+</sup> T cells was observed. It is possible that immune effects may differ in patients with psoriasis, a chronic immune-mediated disease, and this trial should provide further insight into the effects of sitagliptin in psoriasis on immune function.</p><p>There are several other factors in support of sitagliptin therapy being non-immunosuppressive. Clinical trial data show no increase in the incidence of viral infections or malignancy with sitagliptin therapy [<xref ref-type="bibr" rid="CR55">55</xref>]. Twenty patients with human immunodeficiency virus (HIV) who did not have T2DM were treated with sitagliptin 100&#x000a0;mg daily or placebo for 24&#x000a0;weeks and CD4+ T cell count and plasma HIV RNA levels were not affected by sitagliptin treatment [<xref ref-type="bibr" rid="CR56">56</xref>]. There was a reduction in stromal derived factor-1&#x003b1; levels (required to protect T cells from HIV entry) in the sitagliptin group but this did not affect immune or virology status. These data support the lack of a non-immunosuppressive effect with sitagliptin.</p><p>In addition to improvements in hyperglycaemia, sitagliptin treatment has demonstrated improvements in other cardiovascular risk factors relevant to psoriasis patients, although results are inconsistent. Sitagliptin therapy has demonstrated improvements in blood pressure measurements in some studies of patients with T2DM [<xref ref-type="bibr" rid="CR57">57</xref>&#x02013;<xref ref-type="bibr" rid="CR61">61</xref>] although other studies have shown no change in blood pressure with sitagliptin treatment [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR63">63</xref>]. The possible improvement in blood pressure may be related to GLP-1-related natriuresis and vasodilation. Similarly, improvements in lipid parameters have been reported in most [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR64">64</xref>&#x02013;<xref ref-type="bibr" rid="CR66">66</xref>], but not all [<xref ref-type="bibr" rid="CR39">39</xref>], studies of sitagliptin therapy.</p><p>Sitagliptin may also improve cardiac function. Pre-clinical studies have supported the cardioprotective effect of DPP-4 inhibition therapy [<xref ref-type="bibr" rid="CR67">67</xref>&#x02013;<xref ref-type="bibr" rid="CR70">70</xref>], which may be mediated by stromal cell-derived factor-1 [<xref ref-type="bibr" rid="CR70">70</xref>] associated with increased stem cell mobilisation. Two clinical trials evaluating other DPP-4 inhibitors, saxagliptin [<xref ref-type="bibr" rid="CR71">71</xref>] and alogliptin [<xref ref-type="bibr" rid="CR72">72</xref>], did not, however, find a reduction in cardiovascular events in patients with increased cardiovascular risk. The Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin will be informative &#x02013; this is an ongoing large prospective study evaluating the cardiovascular outcomes of patients with T2DM treated with sitagliptin [<xref ref-type="bibr" rid="CR73">73</xref>].</p><p>Psoriasis is associated with multiple metabolic comorbidities including cardiovascular disease. Dipeptidyl peptidase-4 inhibitors, which reduce systemic inflammation and improve metabolic health, may improve psoriasis severity and may also provide an opportunity to treat, and prevent, major comorbidities. This study is the first prospective randomised clinical trial evaluating the potentially beneficial effects of DPP-4 inhibition in patients with psoriasis without diabetes.</p></sec><sec id="Sec13"><title>Trial status</title><p>Recruitment began in November 2013 and is ongoing.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>&#x02206;PASI</term><def><p>the change in psoriasis area and severity index</p></def></def-item><def-item><term>BMI</term><def><p>body mass index</p></def></def-item><def-item><term>CD26</term><def><p>cluster of differentiation 26</p></def></def-item><def-item><term>CRP</term><def><p>C-reactive protein</p></def></def-item><def-item><term>DLQI</term><def><p>Dermatology Life Quality Index</p></def></def-item><def-item><term>DPP-4</term><def><p>dipeptidyl peptidase-4</p></def></def-item><def-item><term>EQ-5D</term><def><p>EuroQoL 5 item questionnaire</p></def></def-item><def-item><term>GLP-1</term><def><p>glucagon-like peptide-1</p></def></def-item><def-item><term>HADS</term><def><p>Hospital Anxiety and Depression Scale</p></def></def-item><def-item><term>HAQ-8</term><def><p>Stanford Health Assessment Questionnaire 8-Item Disability Scale</p></def></def-item><def-item><term>HbA1c</term><def><p>glycated haemoglobin</p></def></def-item><def-item><term>HIV</term><def><p>human immunodeficiency virus</p></def></def-item><def-item><term>HOMA-&#x003b2;</term><def><p>homeostasis model assessment-&#x003b2; cell function</p></def></def-item><def-item><term>HOMA-IR</term><def><p>homeostasis model assessment of insulin resistance</p></def></def-item><def-item><term>IL</term><def><p>interleukin</p></def></def-item><def-item><term>IMP</term><def><p>investigational medicinal product</p></def></def-item><def-item><term>iNKT cells</term><def><p>invariant natural killer T cells</p></def></def-item><def-item><term>MED</term><def><p>minimal erythema dose</p></def></def-item><def-item><term>NB-UVB</term><def><p>narrow-band ultraviolet-B phototherapy</p></def></def-item><def-item><term>PASI</term><def><p>Psoriasis Area and Severity Index</p></def></def-item><def-item><term>T2DM</term><def><p>type 2 diabetes mellitus</p></def></def-item><def-item><term>TNF&#x003b1;</term><def><p>tumour necrosis factor alpha</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Competing interests</bold></p><p>Maeve Lynch is in receipt of a research grant from Merck-Sharp-Dohme and has acted as an advisory board member for Novartis.</p><p>In the last 3&#x000a0;years, Brian Kirby has been in receipt of research grants from Pfizer, Abbvie, and Janssen-Cilag. Brian Kirby is a principal investigator for clinical trials for Abbvie, Janssen-Cilag, Novartis and Merck-Sharp-Dohme. Brian Kirby has acted as a consultant/advisory board member for Pfizer, Abbvie, Janssen-Cilag, Celgene, Novartis and Roche.</p><p>Anne-Marie Tobin has acted as a consultant/advisory board member for Pfizer, Abbvie, Janssen-Cilag and Novartis.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>ML contributed to the conception of the study, participated in its design and coordination and drafted the manuscript. TA contributed to the conception of the study, participated in its design and coordination and reviewed the manuscript. IT contributed to the design of the study, and participated in the acquisition and analysis of data. CS contributed to the conception of the study, participated in its design, and participated in the analysis and interpretation of laboratory data. GK recorded the Psoriasis Area and Severity Index. RH recorded the Psoriasis Area and Severity Index. A-MT contributed to the conception of the study, participated in its design and coordination and reviewed the manuscript for intellectual content. DO&#x02019;S contributed to the conception of the study, participated in its design and coordination, and reviewed the manuscript for intellectual content. BK contributed to the conception of the study, participated in its design and coordination, and reviewed the manuscript for intellectual content. All authors read and approved the final manuscript.</p></fn></fn-group><ack><title>Acknowledgements</title><p>This investigator-initiated study has received funding from Merck-Sharp-Dohme.</p><sec id="FPar1"><title>Disclosures</title><p>No part or whole of the manuscript has ever been published.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parisi</surname><given-names>R</given-names></name><name><surname>Symmons</surname><given-names>DP</given-names></name><name><surname>Griffiths</surname><given-names>CE</given-names></name><name><surname>Ashcroft</surname><given-names>DM</given-names></name></person-group><article-title>Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) Project Team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence</article-title><source>J Invest Dermatol</source><year>2013</year><volume>133</volume><issue>2</issue><fpage>377</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1038/jid.2012.339</pub-id><pub-id pub-id-type="pmid">23014338</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griffiths</surname><given-names>CE</given-names></name><name><surname>Barker</surname><given-names>JN</given-names></name></person-group><article-title>Pathogenesis and clinical features of psoriasis</article-title><source>Lancet</source><year>2007</year><volume>370</volume><issue>9583</issue><fpage>263</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(07)61128-3</pub-id><pub-id pub-id-type="pmid">17658397</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neimann</surname><given-names>AL</given-names></name><name><surname>Shin</surname><given-names>DB</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Margolis</surname><given-names>DJ</given-names></name><name><surname>Troxel</surname><given-names>AB</given-names></name><name><surname>Gelfand</surname><given-names>JM</given-names></name></person-group><article-title>Prevalence of cardiovascular risk factors in patients with psoriasis</article-title><source>J Am Acad Dermatol</source><year>2006</year><volume>55</volume><issue>5</issue><fpage>829</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2006.08.040</pub-id><pub-id pub-id-type="pmid">17052489</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gelfand</surname><given-names>JM</given-names></name><name><surname>Troxel</surname><given-names>AB</given-names></name><name><surname>Lewis</surname><given-names>JD</given-names></name><name><surname>Kurd</surname><given-names>SK</given-names></name><name><surname>Shin</surname><given-names>DB</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><etal/></person-group><article-title>The risk of mortality in patients with psoriasis: results from a population-based study</article-title><source>Arch Dermatol</source><year>2007</year><volume>143</volume><issue>12</issue><fpage>1493</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1001/archderm.143.12.1493</pub-id><pub-id pub-id-type="pmid">18086997</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kimball</surname><given-names>AB</given-names></name><name><surname>Leonardi</surname><given-names>C</given-names></name><name><surname>Stahle</surname><given-names>M</given-names></name><name><surname>Gulliver</surname><given-names>W</given-names></name><name><surname>Chevrier</surname><given-names>M</given-names></name><name><surname>Fakharzadeh</surname><given-names>S</given-names></name><etal/></person-group><article-title>Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR)</article-title><source>Br J Dermatol</source><year>2014</year><volume>171</volume><issue>1</issue><fpage>137</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1111/bjd.13013</pub-id><pub-id pub-id-type="pmid">24684204</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehta</surname><given-names>NN</given-names></name><name><surname>Azfar</surname><given-names>RS</given-names></name><name><surname>Shin</surname><given-names>DB</given-names></name><name><surname>Neimann</surname><given-names>AL</given-names></name><name><surname>Troxel</surname><given-names>AB</given-names></name><name><surname>Gelfand</surname><given-names>JM</given-names></name></person-group><article-title>Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database</article-title><source>Eur Heart J</source><year>2010</year><volume>31</volume><issue>8</issue><fpage>1000</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehp567</pub-id><pub-id pub-id-type="pmid">20037179</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pirro</surname><given-names>M</given-names></name><name><surname>Stingeni</surname><given-names>L</given-names></name><name><surname>Vaudo</surname><given-names>G</given-names></name><name><surname>Mannarino</surname><given-names>MR</given-names></name><name><surname>Ministrini</surname><given-names>S</given-names></name><name><surname>Vonella</surname><given-names>M</given-names></name><etal/></person-group><article-title>Systemic inflammation and imbalance between endothelial injury and repair in patients with psoriasis are associated with preclinical atherosclerosis</article-title><source>Eur J Prev Cardiol</source><year>2015</year><volume>22</volume><issue>8</issue><fpage>1027</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1177/2047487314538858</pub-id><pub-id pub-id-type="pmid">24906366</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="other">Nishioka T, Shinohara M, Tanimoto N, Kumagai C, Hashimoto K. Sitagliptin, a dipeptidyl peptidase-IV inhibitor, improves psoriasis. Dermatology. 2011.</mixed-citation></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="other">Lynch M, Tobin A-M, Ahern T, O&#x02019;Shea D, Kirby B. Sitagliptin for severe psoriasis. Clin Exp Dermatol (in press).</mixed-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Novelli</surname><given-names>M</given-names></name><name><surname>Savoia</surname><given-names>P</given-names></name><name><surname>Fierro</surname><given-names>MT</given-names></name><name><surname>Verrone</surname><given-names>A</given-names></name><name><surname>Quaglino</surname><given-names>P</given-names></name><name><surname>Bernengo</surname><given-names>MG</given-names></name></person-group><article-title>Keratinocytes express dipeptidyl-peptidase IV (CD26) in benign and malignant skin diseases</article-title><source>Br J Dermatol</source><year>1996</year><volume>134</volume><issue>6</issue><fpage>1052</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2133.1996.tb07941.x</pub-id><pub-id pub-id-type="pmid">8763423</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Lingen</surname><given-names>RG</given-names></name><name><surname>van de Kerkhof</surname><given-names>PC</given-names></name><name><surname>Seyger</surname><given-names>MM</given-names></name><name><surname>de Jong</surname><given-names>EM</given-names></name><name><surname>van Rens</surname><given-names>DW</given-names></name><name><surname>Poll</surname><given-names>MK</given-names></name><etal/></person-group><article-title>CD26/dipeptidyl-peptidase IV in psoriatic skin: upregulation and topographical changes</article-title><source>Br J Dermatol</source><year>2008</year><volume>158</volume><issue>6</issue><fpage>1264</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2133.2008.08515.x</pub-id><pub-id pub-id-type="pmid">18384439</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohnuma</surname><given-names>K</given-names></name><name><surname>Hosono</surname><given-names>O</given-names></name><name><surname>Dang</surname><given-names>NH</given-names></name><name><surname>Morimoto</surname><given-names>C</given-names></name></person-group><article-title>Dipeptidyl peptidase in autoimmune pathophysiology</article-title><source>Adv Clin Chem.</source><year>2011</year><volume>53</volume><fpage>51</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1016/B978-0-12-385855-9.00003-5</pub-id><pub-id pub-id-type="pmid">21404914</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heydendael</surname><given-names>VM</given-names></name><name><surname>Spuls</surname><given-names>PI</given-names></name><name><surname>Opmeer</surname><given-names>BC</given-names></name><name><surname>de Borgie</surname><given-names>CA</given-names></name><name><surname>Reitsma</surname><given-names>JB</given-names></name><name><surname>Goldschmidt</surname><given-names>WF</given-names></name><etal/></person-group><article-title>Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis</article-title><source>N Engl J Med</source><year>2003</year><volume>349</volume><issue>7</issue><fpage>658</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa021359</pub-id><pub-id pub-id-type="pmid">12917302</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griffiths</surname><given-names>CE</given-names></name><name><surname>Strober</surname><given-names>BE</given-names></name><name><surname>van de Kerkhof</surname><given-names>P</given-names></name><name><surname>Ho</surname><given-names>V</given-names></name><name><surname>Fidelus-Gort</surname><given-names>R</given-names></name><name><surname>Yeilding</surname><given-names>N</given-names></name><etal/></person-group><article-title>Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis</article-title><source>N Engl J Med</source><year>2010</year><volume>362</volume><issue>2</issue><fpage>118</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0810652</pub-id><pub-id pub-id-type="pmid">20071701</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pepys</surname><given-names>MB</given-names></name><name><surname>Hirschfield</surname><given-names>GM</given-names></name></person-group><article-title>C-reactive protein: a critical update</article-title><source>J Clin Invest</source><year>2003</year><volume>111</volume><issue>12</issue><fpage>1805</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1172/JCI200318921</pub-id><pub-id pub-id-type="pmid">12813013</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hattori</surname><given-names>S</given-names></name></person-group><article-title>Sitagliptin reduces albuminuria in patients with type 2 diabetes</article-title><source>Endocr J</source><year>2011</year><volume>58</volume><issue>1</issue><fpage>69</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1507/endocrj.K10E-382</pub-id><pub-id pub-id-type="pmid">21206136</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Derosa</surname><given-names>G</given-names></name><name><surname>Maffioli</surname><given-names>P</given-names></name><name><surname>Salvadeo</surname><given-names>SA</given-names></name><name><surname>Ferrari</surname><given-names>I</given-names></name><name><surname>Ragonesi</surname><given-names>PD</given-names></name><name><surname>Querci</surname><given-names>F</given-names></name><etal/></person-group><article-title>Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients</article-title><source>Metabolism</source><year>2010</year><volume>59</volume><issue>6</issue><fpage>887</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1016/j.metabol.2009.10.007</pub-id><pub-id pub-id-type="pmid">20015525</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams-Herman</surname><given-names>D</given-names></name><name><surname>Engel</surname><given-names>SS</given-names></name><name><surname>Round</surname><given-names>E</given-names></name><name><surname>Johnson</surname><given-names>J</given-names></name><name><surname>Golm</surname><given-names>GT</given-names></name><name><surname>Guo</surname><given-names>H</given-names></name><etal/></person-group><article-title>Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes</article-title><source>BMC Endocr Disord.</source><year>2010</year><volume>10</volume><fpage>7</fpage><pub-id pub-id-type="doi">10.1186/1472-6823-10-7</pub-id><pub-id pub-id-type="pmid">20412573</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamanna</surname><given-names>C</given-names></name><name><surname>Monami</surname><given-names>M</given-names></name><name><surname>Bartoli</surname><given-names>N</given-names></name><name><surname>Zannoni</surname><given-names>S</given-names></name><name><surname>Mannucci</surname><given-names>E</given-names></name></person-group><article-title>Dipeptidyl peptidase-4 inhibitors and cardiovascular events: a protective effect?</article-title><source>Diabetologia.</source><year>2011</year><volume>54 Suppl 1</volume><fpage>S109</fpage></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Satoh-Asahara</surname><given-names>N</given-names></name><name><surname>Sasaki</surname><given-names>Y</given-names></name><name><surname>Wada</surname><given-names>H</given-names></name><name><surname>Tochiya</surname><given-names>M</given-names></name><name><surname>Iguchi</surname><given-names>A</given-names></name><name><surname>Nakagawachi</surname><given-names>R</given-names></name><etal/></person-group><article-title>A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients</article-title><source>Metabolism</source><year>2013</year><volume>62</volume><issue>3</issue><fpage>347</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1016/j.metabol.2012.09.004</pub-id><pub-id pub-id-type="pmid">23062489</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tremblay</surname><given-names>AJ</given-names></name><name><surname>Lamarche</surname><given-names>B</given-names></name><name><surname>Deacon</surname><given-names>CF</given-names></name><name><surname>Weisnagel</surname><given-names>SJ</given-names></name><name><surname>Couture</surname><given-names>P</given-names></name></person-group><article-title>Effects of sitagliptin therapy on markers of low-grade inflammation and cell adhesion molecules in patients with type 2 diabetes</article-title><source>Metabolism</source><year>2014</year><volume>63</volume><issue>9</issue><fpage>1141</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.metabol.2014.06.004</pub-id><pub-id pub-id-type="pmid">25034387</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Makdissi</surname><given-names>A</given-names></name><name><surname>Ghanim</surname><given-names>H</given-names></name><name><surname>Vora</surname><given-names>M</given-names></name><name><surname>Green</surname><given-names>K</given-names></name><name><surname>Abuaysheh</surname><given-names>S</given-names></name><name><surname>Chaudhuri</surname><given-names>A</given-names></name><etal/></person-group><article-title>Sitagliptin exerts an antinflammatory action</article-title><source>J Clin Endocrinol Metab</source><year>2012</year><volume>97</volume><issue>9</issue><fpage>3333</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1210/jc.2012-1544</pub-id><pub-id pub-id-type="pmid">22745245</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gisondi</surname><given-names>P</given-names></name><name><surname>Malerba</surname><given-names>M</given-names></name><name><surname>Malara</surname><given-names>G</given-names></name><name><surname>Puglisi Guerra</surname><given-names>A</given-names></name><name><surname>Sala</surname><given-names>R</given-names></name><name><surname>Radaeli</surname><given-names>A</given-names></name><etal/></person-group><article-title>C-reactive protein and markers for thrombophilia in patients with chronic plaque psoriasis</article-title><source>Int J Immunopathol Pharmacol</source><year>2010</year><volume>23</volume><issue>4</issue><fpage>1195</fpage><lpage>202</lpage><pub-id pub-id-type="pmid">21244768</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="other">Nisa N, Ahmed Q. High-sensitivity C-reactive protein in psoriasis. Int J Dermatol. 2011.</mixed-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chodorowksal</surname><given-names>G</given-names></name><name><surname>Wojnowska Duszkiewicz-Borowiec</surname><given-names>M</given-names></name></person-group><article-title>C-reactive protein and alpha2-macroglobulin plasma activity in medium-severe and severe psoriasis</article-title><source>J Eur Acad Dermatol Venereol</source><year>2004</year><volume>18</volume><issue>2</issue><fpage>180</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1111/j.1468-3083.2004.00863.x</pub-id><pub-id pub-id-type="pmid">15009298</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tobin</surname><given-names>AM</given-names></name><name><surname>Hackett</surname><given-names>CB</given-names></name><name><surname>Rogers</surname><given-names>S</given-names></name><name><surname>Collins</surname><given-names>P</given-names></name><name><surname>Richards</surname><given-names>HL</given-names></name><name><surname>O&#x02019;Shea</surname><given-names>D</given-names></name><etal/></person-group><article-title>Body mass index, waist circumference and HOMA-IR correlate with the Psoriasis Area and Severity Index in patients with psoriasis receiving phototherapy</article-title><source>Br J Dermatol</source><year>2014</year><volume>171</volume><issue>2</issue><fpage>436</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1111/bjd.12914</pub-id><pub-id pub-id-type="pmid">24641699</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mittal</surname><given-names>R</given-names></name><name><surname>Malhotra</surname><given-names>S</given-names></name><name><surname>Pandhi</surname><given-names>P</given-names></name><name><surname>Kaur</surname><given-names>I</given-names></name><name><surname>Dogra</surname><given-names>S</given-names></name></person-group><article-title>Efficacy and safety of combination acitretin and pioglitazone therapy in patients with moderate to severe chronic plaque-type psoriasis: a randomized, double-blind, placebo-controlled clinical trial</article-title><source>Arch Dermatol.</source><year>2009</year><volume>145</volume><fpage>387</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1001/archdermatol.2009.5</pub-id><pub-id pub-id-type="pmid">19380660</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Markham</surname><given-names>T</given-names></name><name><surname>Rogers</surname><given-names>S</given-names></name><name><surname>Collins</surname><given-names>P</given-names></name></person-group><article-title>Narrowband UV-B (TL-01) phototherapy vs oral 8-methoxypsoralen psoralen-UV-A for the treatment of chronic plaque psoriasis</article-title><source>Arch Dermatol</source><year>2003</year><volume>139</volume><issue>3</issue><fpage>325</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1001/archderm.139.3.325</pub-id><pub-id pub-id-type="pmid">12622624</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kleinpenning</surname><given-names>MM</given-names></name><name><surname>Smits</surname><given-names>T</given-names></name><name><surname>Boezeman</surname><given-names>J</given-names></name><name><surname>van de Kerkhof</surname><given-names>PC</given-names></name><name><surname>Evers</surname><given-names>AW</given-names></name><name><surname>Gerritsen</surname><given-names>MJ</given-names></name></person-group><article-title>Narrowband ultraviolet B therapy in psoriasis: randomized double-blind comparison of high-dose and low-dose irradiation regimens</article-title><source>Br J Dermatol</source><year>2009</year><volume>161</volume><issue>6</issue><fpage>1351</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2133.2009.09212.x</pub-id><pub-id pub-id-type="pmid">19466961</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thielitz</surname><given-names>A</given-names></name><name><surname>Reinhold</surname><given-names>D</given-names></name><name><surname>Vetter</surname><given-names>R</given-names></name><name><surname>Bank</surname><given-names>U</given-names></name><name><surname>Helmuth</surname><given-names>M</given-names></name><name><surname>Hartig</surname><given-names>R</given-names></name><etal/></person-group><article-title>Inhibitors of dipeptidyl peptidase IV and aminopeptidase N target major pathogenetic steps in acne initiation</article-title><source>J Invest Dermatol</source><year>2007</year><volume>127</volume><issue>5</issue><fpage>1042</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1038/sj.jid.5700439</pub-id><pub-id pub-id-type="pmid">16778789</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drucker</surname><given-names>DJ</given-names></name><name><surname>Sherman</surname><given-names>SI</given-names></name><name><surname>Gorelick</surname><given-names>FS</given-names></name><name><surname>Bergenstal</surname><given-names>RM</given-names></name><name><surname>Sherwin</surname><given-names>RS</given-names></name><name><surname>Buse</surname><given-names>JB</given-names></name></person-group><article-title>Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits</article-title><source>Diabetes Care</source><year>2010</year><volume>33</volume><issue>2</issue><fpage>428</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.2337/dc09-1499</pub-id><pub-id pub-id-type="pmid">20103558</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hossler</surname><given-names>EW</given-names></name><name><surname>Maroon</surname><given-names>MS</given-names></name><name><surname>Mowad</surname><given-names>CM</given-names></name></person-group><article-title>Gastric bypass surgery improves psoriasis</article-title><source>J Am Acad Dermatol</source><year>2011</year><volume>65</volume><issue>1</issue><fpage>198</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2010.01.001</pub-id><pub-id pub-id-type="pmid">20655127</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hogan</surname><given-names>AE</given-names></name><name><surname>Tobin</surname><given-names>AM</given-names></name><name><surname>Ahern</surname><given-names>T</given-names></name><name><surname>Corrigan</surname><given-names>MA</given-names></name><name><surname>Gaoatswe</surname><given-names>G</given-names></name><name><surname>Jackson</surname><given-names>R</given-names></name><etal/></person-group><article-title>Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis</article-title><source>Diabetologia</source><year>2011</year><volume>54</volume><issue>11</issue><fpage>2745</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1007/s00125-011-2232-3</pub-id><pub-id pub-id-type="pmid">21744074</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faurschou</surname><given-names>A</given-names></name><name><surname>Knop</surname><given-names>FK</given-names></name><name><surname>Thyssen</surname><given-names>JP</given-names></name><name><surname>Zachariae</surname><given-names>C</given-names></name><name><surname>Skov</surname><given-names>L</given-names></name><name><surname>Vilsboll</surname><given-names>T</given-names></name></person-group><article-title>Improvement in psoriasis after treatment with the glucagon-like peptide-1 receptor agonist liraglutide</article-title><source>Acta Diabetol</source><year>2014</year><volume>51</volume><issue>1</issue><fpage>147</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1007/s00592-011-0359-9</pub-id><pub-id pub-id-type="pmid">22160246</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahern</surname><given-names>T</given-names></name><name><surname>Tobin</surname><given-names>AM</given-names></name><name><surname>Corrigan</surname><given-names>M</given-names></name><name><surname>Hogan</surname><given-names>A</given-names></name><name><surname>Sweeney</surname><given-names>C</given-names></name><name><surname>Kirby</surname><given-names>B</given-names></name><etal/></person-group><article-title>Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study</article-title><source>J Eur Acad Dermatol Venereol.</source><year>2013</year><volume>27</volume><fpage>1440</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1111/j.1468-3083.2012.04609.x</pub-id><pub-id pub-id-type="pmid">22691169</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buysschaert</surname><given-names>M</given-names></name><name><surname>Baeck</surname><given-names>M</given-names></name><name><surname>Preumont</surname><given-names>V</given-names></name><name><surname>Marot</surname><given-names>L</given-names></name><name><surname>Hendrickx</surname><given-names>E</given-names></name><name><surname>Van Belle</surname><given-names>A</given-names></name><etal/></person-group><article-title>Improvement of psoriasis during glucagon-like peptide-1 analogue therapy in type 2 diabetes is associated with decreasing dermal gammadelta T-cell number: a prospective case-series study</article-title><source>Br J Dermatol</source><year>2014</year><volume>171</volume><issue>1</issue><fpage>155</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1111/bjd.12886</pub-id><pub-id pub-id-type="pmid">24506139</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><mixed-citation publication-type="other">Faurschou A, Gyldenlove M, Rohde U, Thyssen JP, Zachariae C, Skov L, et al. Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients &#x02013; a randomized placebo-controlled trial. J Eur Acad Dermatol Venereol. 2014.</mixed-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koren</surname><given-names>S</given-names></name><name><surname>Shemesh-Bar</surname><given-names>L</given-names></name><name><surname>Tirosh</surname><given-names>A</given-names></name><name><surname>Peleg</surname><given-names>RK</given-names></name><name><surname>Berman</surname><given-names>S</given-names></name><name><surname>Hamad</surname><given-names>RA</given-names></name><etal/></person-group><article-title>The effect of sitagliptin versus glibenclamide on arterial stiffness, blood pressure, lipids, and inflammation in type 2 diabetes mellitus patients</article-title><source>Diabetes Technol Ther</source><year>2012</year><volume>14</volume><fpage>561</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1089/dia.2011.0296</pub-id><pub-id pub-id-type="pmid">22512265</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choe</surname><given-names>EY</given-names></name><name><surname>Cho</surname><given-names>Y</given-names></name><name><surname>Choi</surname><given-names>Y</given-names></name><name><surname>Yun</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>HJ</given-names></name><name><surname>Kwon</surname><given-names>O</given-names></name><etal/></person-group><article-title>The effect of DPP-4 inhibitors on metabolic parameters in patients with type 2 diabetes</article-title><source>Diabetes Metab J</source><year>2014</year><volume>38</volume><fpage>211</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.4093/dmj.2014.38.3.211</pub-id><pub-id pub-id-type="pmid">25003075</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aschner</surname><given-names>P</given-names></name><name><surname>Katzeff</surname><given-names>HL</given-names></name><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>Sunga</surname><given-names>S</given-names></name><name><surname>Williams-Herman</surname><given-names>D</given-names></name><name><surname>Kaufman</surname><given-names>KD</given-names></name><etal/></person-group><article-title>Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes</article-title><source>Diabetes Obes Metab</source><year>2010</year><volume>12</volume><issue>3</issue><fpage>252</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1111/j.1463-1326.2009.01187.x</pub-id><pub-id pub-id-type="pmid">20070351</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raz</surname><given-names>I</given-names></name><name><surname>Hanefeld</surname><given-names>M</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Caria</surname><given-names>C</given-names></name><name><surname>Williams-Herman</surname><given-names>D</given-names></name><name><surname>Khatami</surname><given-names>H</given-names></name></person-group><article-title>Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus</article-title><source>Diabetologia</source><year>2006</year><volume>49</volume><issue>11</issue><fpage>2564</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1007/s00125-006-0416-z</pub-id><pub-id pub-id-type="pmid">17001471</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanefeld</surname><given-names>M</given-names></name><name><surname>Herman</surname><given-names>GA</given-names></name><name><surname>Wu</surname><given-names>M</given-names></name><name><surname>Mickel</surname><given-names>C</given-names></name><name><surname>Sanchez</surname><given-names>M</given-names></name><name><surname>Stein</surname><given-names>PP</given-names></name></person-group><article-title>Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes</article-title><source>Curr Med Res Opin</source><year>2007</year><volume>23</volume><issue>6</issue><fpage>1329</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1185/030079907X188152</pub-id><pub-id pub-id-type="pmid">17559733</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname><given-names>R</given-names></name><name><surname>Wu</surname><given-names>M</given-names></name><name><surname>Sanchez</surname><given-names>M</given-names></name><name><surname>Stein</surname><given-names>P</given-names></name></person-group><article-title>Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12&#x000a0;weeks in patients with type 2 diabetes</article-title><source>Int J Clin Pract</source><year>2007</year><volume>61</volume><issue>1</issue><fpage>171</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1111/j.1742-1241.2006.01246.x</pub-id><pub-id pub-id-type="pmid">17156104</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nonaka</surname><given-names>K</given-names></name><name><surname>Kakikawa</surname><given-names>T</given-names></name><name><surname>Sato</surname><given-names>A</given-names></name><name><surname>Okuyama</surname><given-names>K</given-names></name><name><surname>Fujimoto</surname><given-names>G</given-names></name><name><surname>Kato</surname><given-names>N</given-names></name><etal/></person-group><article-title>Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes</article-title><source>Diabetes Res Clin Pract</source><year>2008</year><volume>79</volume><issue>2</issue><fpage>291</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.diabres.2007.08.021</pub-id><pub-id pub-id-type="pmid">17933414</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Derosa</surname><given-names>G</given-names></name><name><surname>Carbone</surname><given-names>A</given-names></name><name><surname>D&#x02019;Angelo</surname><given-names>A</given-names></name><name><surname>Querci</surname><given-names>F</given-names></name><name><surname>Fogari</surname><given-names>E</given-names></name><name><surname>Cicero</surname><given-names>AF</given-names></name><etal/></person-group><article-title>Variations in inflammatory biomarkers following the addition of sitagliptin in patients with type 2 diabetes not controlled with metformin</article-title><source>Intern Med</source><year>2013</year><volume>52</volume><issue>19</issue><fpage>2179</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.2169/internalmedicine.52.8175</pub-id><pub-id pub-id-type="pmid">24088749</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Derosa</surname><given-names>G</given-names></name><name><surname>Carbone</surname><given-names>A</given-names></name><name><surname>Franzetti</surname><given-names>I</given-names></name><name><surname>Querci</surname><given-names>F</given-names></name><name><surname>Fogari</surname><given-names>E</given-names></name><name><surname>Bianchi</surname><given-names>L</given-names></name><etal/></person-group><article-title>Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, beta-cell function and insulin resistance in type 2 diabetic patients</article-title><source>Diabetes Res Clin Pract</source><year>2012</year><volume>98</volume><issue>1</issue><fpage>51</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1016/j.diabres.2012.05.022</pub-id><pub-id pub-id-type="pmid">22682949</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wainstein</surname><given-names>J</given-names></name><name><surname>Katz</surname><given-names>L</given-names></name><name><surname>Engel</surname><given-names>SS</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Golm</surname><given-names>GT</given-names></name><name><surname>Hussain</surname><given-names>S</given-names></name><etal/></person-group><article-title>Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes</article-title><source>Diabetes Obes Metab</source><year>2012</year><volume>14</volume><issue>5</issue><fpage>409</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1111/j.1463-1326.2011.01530.x</pub-id><pub-id pub-id-type="pmid">22059736</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Derosa</surname><given-names>G</given-names></name><name><surname>Cicero</surname><given-names>AF</given-names></name><name><surname>Franzetti</surname><given-names>IG</given-names></name><name><surname>Querci</surname><given-names>F</given-names></name><name><surname>Carbone</surname><given-names>A</given-names></name><name><surname>Piccinni</surname><given-names>MN</given-names></name><etal/></person-group><article-title>A randomized, double-blind, comparative therapy evaluating sitagliptin versus glibenclamide in type 2 diabetes patients already treated with pioglitazone and metformin: a 3-year study</article-title><source>Diabetes Technol Ther</source><year>2013</year><volume>15</volume><issue>3</issue><fpage>214</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1089/dia.2012.0272</pub-id><pub-id pub-id-type="pmid">23427864</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Derosa</surname><given-names>G</given-names></name><name><surname>Carbone</surname><given-names>A</given-names></name><name><surname>D&#x02019;Angelo</surname><given-names>A</given-names></name><name><surname>Querci</surname><given-names>F</given-names></name><name><surname>Fogari</surname><given-names>E</given-names></name><name><surname>Cicero</surname><given-names>AF</given-names></name><etal/></person-group><article-title>A randomized, double-blind, placebo-controlled trial evaluating sitagliptin action on insulin resistance parameters and beta-cell function</article-title><source>Expert Opin Pharmacother</source><year>2012</year><volume>13</volume><issue>17</issue><fpage>2433</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1517/14656566.2012.730519</pub-id><pub-id pub-id-type="pmid">23061989</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Derosa</surname><given-names>G</given-names></name><name><surname>Ragonesi</surname><given-names>PD</given-names></name><name><surname>Fogari</surname><given-names>E</given-names></name><name><surname>Cicero</surname><given-names>AF</given-names></name><name><surname>Bianchi</surname><given-names>L</given-names></name><name><surname>Bonaventura</surname><given-names>A</given-names></name><etal/></person-group><article-title>Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile: a 2-year study evaluation</article-title><source>Fundam Clin Pharmacol</source><year>2014</year><volume>28</volume><issue>2</issue><fpage>221</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1111/fcp.12001</pub-id><pub-id pub-id-type="pmid">23039403</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aschner</surname><given-names>P</given-names></name><name><surname>Kipnes</surname><given-names>MS</given-names></name><name><surname>Lunceford</surname><given-names>JK</given-names></name><name><surname>Sanchez</surname><given-names>M</given-names></name><name><surname>Mickel</surname><given-names>C</given-names></name><name><surname>Williams-Herman</surname><given-names>DE</given-names></name></person-group><article-title>Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes</article-title><source>Diabetes Care</source><year>2006</year><volume>29</volume><issue>12</issue><fpage>2632</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.2337/dc06-0703</pub-id><pub-id pub-id-type="pmid">17130196</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>Q</given-names></name><name><surname>Wu</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>YJ</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Zhao</surname><given-names>YY</given-names></name><name><surname>Liang</surname><given-names>YY</given-names></name></person-group><article-title>Comparative effects of sitagliptin and metformin in patients with type 2 diabetes mellitus: a meta-analysis</article-title><source>Curr Med Res Opin</source><year>2013</year><volume>29</volume><issue>11</issue><fpage>1487</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1185/03007995.2013.833090</pub-id><pub-id pub-id-type="pmid">23927568</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonora</surname><given-names>E</given-names></name><name><surname>Targher</surname><given-names>G</given-names></name><name><surname>Alberiche</surname><given-names>M</given-names></name><name><surname>Bonadonna</surname><given-names>RC</given-names></name><name><surname>Saggiani</surname><given-names>F</given-names></name><name><surname>Zenere</surname><given-names>MB</given-names></name><etal/></person-group><article-title>Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity</article-title><source>Diabetes Care</source><year>2000</year><volume>23</volume><issue>1</issue><fpage>57</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.2337/diacare.23.1.57</pub-id><pub-id pub-id-type="pmid">10857969</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Price</surname><given-names>JD</given-names></name><name><surname>Linder</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>WP</given-names></name><name><surname>Zimmermann</surname><given-names>B</given-names></name><name><surname>Rother</surname><given-names>KI</given-names></name><name><surname>Malek</surname><given-names>R</given-names></name><etal/></person-group><article-title>Effects of short-term sitagliptin treatment on immune parameters in healthy individuals, a randomized placebo-controlled study</article-title><source>Clin Exp Immunol</source><year>2013</year><volume>174</volume><issue>1</issue><fpage>120</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1111/cei.12144</pub-id><pub-id pub-id-type="pmid">23711188</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><mixed-citation publication-type="other">Scheen AJ. Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes. Expert Opin Drug Saf. 2015:1-20. Epub 2015/01/30.</mixed-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goodwin</surname><given-names>SR</given-names></name><name><surname>Reeds</surname><given-names>DN</given-names></name><name><surname>Royal</surname><given-names>M</given-names></name><name><surname>Struthers</surname><given-names>H</given-names></name><name><surname>Laciny</surname><given-names>E</given-names></name><name><surname>Yarasheski</surname><given-names>KE</given-names></name></person-group><article-title>Dipeptidyl peptidase IV inhibition does not adversely affect immune or virological status in HIV infected men and women: a pilot safety study</article-title><source>J Clin Endocrinol Metab</source><year>2013</year><volume>98</volume><issue>2</issue><fpage>743</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1210/jc.2012-3532</pub-id><pub-id pub-id-type="pmid">23264399</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawasaki</surname><given-names>I</given-names></name><name><surname>Hiura</surname><given-names>Y</given-names></name><name><surname>Tamai</surname><given-names>A</given-names></name><name><surname>Yoshida</surname><given-names>Y</given-names></name><name><surname>Yakusiji</surname><given-names>Y</given-names></name><name><surname>Ikuno</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Sitagliptin reduces the urine albumin-to-creatinine ratio in type 2 diabetes through decreasing both blood pressure and estimated glomerular filtration rate 2</article-title><source>J Diabetes</source><year>2015</year><volume>7</volume><issue>1</issue><fpage>41</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1111/1753-0407.12153</pub-id><pub-id pub-id-type="pmid">24661437</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakamoto</surname><given-names>Y</given-names></name><name><surname>Oyama</surname><given-names>J</given-names></name><name><surname>Ikeda</surname><given-names>H</given-names></name><name><surname>Kuroki</surname><given-names>S</given-names></name><name><surname>Gondo</surname><given-names>S</given-names></name><name><surname>Iwamoto</surname><given-names>T</given-names></name><etal/></person-group><article-title>Effects of sitagliptin beyond glycemic control: focus on quality of life</article-title><source>Cardiovasc Diabetol.</source><year>2013</year><volume>12</volume><fpage>35</fpage><pub-id pub-id-type="doi">10.1186/1475-2840-12-35</pub-id><pub-id pub-id-type="pmid">23432786</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ogawa</surname><given-names>S</given-names></name><name><surname>Ishiki</surname><given-names>M</given-names></name><name><surname>Nako</surname><given-names>K</given-names></name><name><surname>Okamura</surname><given-names>M</given-names></name><name><surname>Senda</surname><given-names>M</given-names></name><name><surname>Mori</surname><given-names>T</given-names></name><etal/></person-group><article-title>Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes</article-title><source>Tohoku J Exp Med</source><year>2011</year><volume>223</volume><issue>2</issue><fpage>133</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1620/tjem.223.133</pub-id><pub-id pub-id-type="pmid">21304217</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kubota</surname><given-names>A</given-names></name><name><surname>Maeda</surname><given-names>H</given-names></name><name><surname>Kanamori</surname><given-names>A</given-names></name><name><surname>Matoba</surname><given-names>K</given-names></name><name><surname>Jin</surname><given-names>Y</given-names></name><name><surname>Minagawa</surname><given-names>F</given-names></name><etal/></person-group><article-title>Pleiotropic effects of sitagliptin in the treatment of type 2 diabetes mellitus patients</article-title><source>J Clin Med Res</source><year>2012</year><volume>4</volume><issue>5</issue><fpage>309</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">23024732</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mistry</surname><given-names>GC</given-names></name><name><surname>Maes</surname><given-names>AL</given-names></name><name><surname>Lasseter</surname><given-names>KC</given-names></name><name><surname>Davies</surname><given-names>MJ</given-names></name><name><surname>Gottesdiener</surname><given-names>KM</given-names></name><name><surname>Wagner</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension</article-title><source>J Clin Pharmacol</source><year>2008</year><volume>48</volume><issue>5</issue><fpage>592</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1177/0091270008316885</pub-id><pub-id pub-id-type="pmid">18353996</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barbieri</surname><given-names>M</given-names></name><name><surname>Rizzo</surname><given-names>MR</given-names></name><name><surname>Marfella</surname><given-names>R</given-names></name><name><surname>Boccardi</surname><given-names>V</given-names></name><name><surname>Esposito</surname><given-names>A</given-names></name><name><surname>Pansini</surname><given-names>A</given-names></name><etal/></person-group><article-title>Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors</article-title><source>Atherosclerosis</source><year>2013</year><volume>227</volume><issue>2</issue><fpage>349</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2012.12.018</pub-id><pub-id pub-id-type="pmid">23375680</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yanai</surname><given-names>H</given-names></name><name><surname>Adachi</surname><given-names>H</given-names></name><name><surname>Hamasaki</surname><given-names>H</given-names></name><name><surname>Masui</surname><given-names>Y</given-names></name><name><surname>Yoshikawa</surname><given-names>R</given-names></name><name><surname>Moriyama</surname><given-names>S</given-names></name><etal/></person-group><article-title>Effects of 6-month sitagliptin treatment on glucose and lipid metabolism, blood pressure, body weight and renal function in type 2 diabetic patients: a chart-based analysis</article-title><source>J Clin Med Res</source><year>2012</year><volume>4</volume><issue>4</issue><fpage>251</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">22870172</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monami</surname><given-names>M</given-names></name><name><surname>Lamanna</surname><given-names>C</given-names></name><name><surname>Desideri</surname><given-names>CM</given-names></name><name><surname>Mannucci</surname><given-names>E</given-names></name></person-group><article-title>DPP-4 inhibitors and lipids: systematic review and meta-analysis</article-title><source>Adv Ther</source><year>2012</year><volume>29</volume><issue>1</issue><fpage>14</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1007/s12325-011-0088-z</pub-id><pub-id pub-id-type="pmid">22215383</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tremblay</surname><given-names>AJ</given-names></name><name><surname>Lamarche</surname><given-names>B</given-names></name><name><surname>Deacon</surname><given-names>CF</given-names></name><name><surname>Weisnagel</surname><given-names>SJ</given-names></name><name><surname>Couture</surname><given-names>P</given-names></name></person-group><article-title>Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes</article-title><source>Diabetes Obes Metab</source><year>2011</year><volume>13</volume><issue>4</issue><fpage>366</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1111/j.1463-1326.2011.01362.x</pub-id><pub-id pub-id-type="pmid">21226820</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>C</given-names></name><name><surname>Dash</surname><given-names>S</given-names></name><name><surname>Morgantini</surname><given-names>C</given-names></name><name><surname>Patterson</surname><given-names>BW</given-names></name><name><surname>Lewis</surname><given-names>GF</given-names></name></person-group><article-title>Sitagliptin, a DPP-4 inhibitor, acutely inhibits intestinal lipoprotein particle secretion in healthy humans</article-title><source>Diabetes</source><year>2014</year><volume>63</volume><issue>7</issue><fpage>2394</fpage><lpage>401</lpage><pub-id pub-id-type="doi">10.2337/db13-1654</pub-id><pub-id pub-id-type="pmid">24584549</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sauve</surname><given-names>M</given-names></name><name><surname>Ban</surname><given-names>K</given-names></name><name><surname>Momen</surname><given-names>MA</given-names></name><name><surname>Zhou</surname><given-names>YQ</given-names></name><name><surname>Henkelman</surname><given-names>RM</given-names></name><name><surname>Husain</surname><given-names>M</given-names></name><etal/></person-group><article-title>Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice</article-title><source>Diabetes</source><year>2010</year><volume>59</volume><issue>4</issue><fpage>1063</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.2337/db09-0955</pub-id><pub-id pub-id-type="pmid">20097729</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>Y</given-names></name><name><surname>Keyes</surname><given-names>KT</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Perez-Polo</surname><given-names>JR</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Birnbaum</surname><given-names>Y</given-names></name></person-group><article-title>The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2010</year><volume>298</volume><issue>5</issue><fpage>H1454</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.00867.2009</pub-id><pub-id pub-id-type="pmid">20207816</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huisamen</surname><given-names>B</given-names></name><name><surname>Genis</surname><given-names>A</given-names></name><name><surname>Marais</surname><given-names>E</given-names></name><name><surname>Lochner</surname><given-names>A</given-names></name></person-group><article-title>Pre-treatment with a DPP-4 inhibitor is infarct sparing in hearts from obese, pre-diabetic rats</article-title><source>Cardiovasc Drugs Ther</source><year>2011</year><volume>25</volume><issue>1</issue><fpage>13</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1007/s10557-010-6271-7</pub-id><pub-id pub-id-type="pmid">21088878</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Theiss</surname><given-names>HD</given-names></name><name><surname>Gross</surname><given-names>L</given-names></name><name><surname>Vallaster</surname><given-names>M</given-names></name><name><surname>David</surname><given-names>R</given-names></name><name><surname>Brunner</surname><given-names>S</given-names></name><name><surname>Brenner</surname><given-names>C</given-names></name><etal/></person-group><article-title>Antidiabetic gliptins in combination with G-CSF enhances myocardial function and survival after acute myocardial infarction</article-title><source>Int J Cardiol</source><year>2013</year><volume>168</volume><issue>4</issue><fpage>3359</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1016/j.ijcard.2013.04.121</pub-id><pub-id pub-id-type="pmid">23669105</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scirica</surname><given-names>BM</given-names></name><name><surname>Bhatt</surname><given-names>DL</given-names></name><name><surname>Braunwald</surname><given-names>E</given-names></name><name><surname>Steg</surname><given-names>PG</given-names></name><name><surname>Davidson</surname><given-names>J</given-names></name><name><surname>Hirshberg</surname><given-names>B</given-names></name><etal/></person-group><article-title>Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus</article-title><source>N Engl J Med</source><year>2013</year><volume>369</volume><issue>14</issue><fpage>1317</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1307684</pub-id><pub-id pub-id-type="pmid">23992601</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>WB</given-names></name><name><surname>Cannon</surname><given-names>CP</given-names></name><name><surname>Heller</surname><given-names>SR</given-names></name><name><surname>Nissen</surname><given-names>SE</given-names></name><name><surname>Bergenstal</surname><given-names>RM</given-names></name><name><surname>Bakris</surname><given-names>GL</given-names></name><etal/></person-group><article-title>Alogliptin after acute coronary syndrome in patients with type 2 diabetes</article-title><source>N Engl J Med</source><year>2013</year><volume>369</volume><issue>14</issue><fpage>1327</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1305889</pub-id><pub-id pub-id-type="pmid">23992602</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><mixed-citation publication-type="other">Bethel MA, Green JB, Milton J, Tajar A, Engel SS, Califf RM, et al. Regional, age, and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). Diabetes Obes Metabol. 2015.</mixed-citation></ref></ref-list></back></article>